Learn More About Benefits of
Becoming a Sponsor!
Industry
Increased Awareness & Networking
- Improve Patient & Physician Awareness through uploaded Sponsor-controlled Educational Content, Trial Criteria, Presentations & Publications,all related to your investigational product.
- Market Globallyon a highly visible platform to a highly focused audience including cancer patients who can greatly benefit enrolling on yout trial.
- Network on a Single Platformand align with a Multitude
of Professionals from several areas of the Theranostic Industry
including:
-
Sponsors
-
CROs
-
CDMOs
-
Couriers
-
Advocacy Groups
-
Venture Capitalists
-
Medical Societies
-
Physicians
-
- Promote Upcoming Theranostic Conferences
- Access to Real-time Trial Stats & Site Stats
Collaborations
Advancing the field of cancer Theranostics requires a multitude of industries working together. Companies provide discovery, development, production, clinical trial management, radioactive courier services, equipment suppliers, staffing, dosimetry, capital investment, regulatory agencies, cancer centers, and many more.
About Us
TheranosticTrials was developed through the collaboration of 2 key opinion leaders in the field of Radiopharmaceuticals. Drs. Luke Nordquist and Oliver Sartor saw the need for a such a web-based tool to provide patient education & ultimately improve access to the rapidly expanding field of radiopharmaceutical clinical trials. Patients globally are seeking access to these highly sought-after clinical trials which are providing new hope.
Distinguished Investigator
A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.
Conferences
High Country Nuclear Medicine Conference
High Country continues to attract and blend experts from academia and industry, with leaders in medical specialties, the regulatory agencies and health care researchers in an informal setting to facilitate dialog and an exchange of ideas. The meeting consists of six to seven hours of structured sessions per day (8 sessions total). In between sessions, roundtable discussions will be held and there are ample opportunities for independent meetings and networking.EANM '25
The EANM Annual Congress is a truly global event, attracting about 10,000 participants from all over the world. This diverse gathering of professionals provides a rich platform for the exchange of ideas, fostering international collaboration and innovation. We are committed to exploring novel formats and interactions with experts, ensuring that our congress remains at the forefront of scientific discourse and professional development. One of the highlights of this year’s congress will be the continued focus on novel advances in theranostics. This rapidly evolving field continues to revolutionize our approach to diagnosis and treatment, offering unprecedented precision and personalized care for our patients. We have an exciting program lined up, featuring leading experts who will share their insights and latest research findings. But our congress is also designed to cater to all fields of research and clinical activity within nuclear medicine. We have specific tracks dedicated to all the various specialties, ensuring that every participant can find sessions relevant to their interests and expertise. Whether you are involved in clinical practice, research, or education, there will be something for you at the EANM’25.PEGS Boston
Radiopharmaceutical therapies are a rapidly advancing approach in medicine that leverages the unique properties of radioactive isotopes to selectively target and treat various diseases, particularly cancers. These targeted therapies have shown promising results in the treatment of a variety of solid tumors and hematological malignancies, including prostate cancer, neuroendocrine tumors, lymphoma, and select forms of leukemia. As the field continues to advance, researchers are exploring new targeting strategies, novel radioisotope applications, and personalized treatment approaches to further improve patient outcomes. We are inviting leading experts to share their case studies and showcase the tremendous potential of radiopharmaceutical therapies to transform patient care.35th Annual European Pharma Congress
The main theme of the conference is “Discover the Future : The Next Era of Pharma Awaits”. This strategic congress will offer speakers the opportunity to network with like-minded experts while discussing how to address the challenges confronting pharmaceutical product development and synthesis today. It features keynote presentations, oral presentations, poster presentations, symposia, workshops, exhibitions, and career development sessions.Targeted Radioligand Therapies
Cambridge Healthtech Institute's Inaugural event will explore the latest advancements, challenges, and opportunities in this rapidly evolving field, fostering collaborations among researchers, clinicians, and industry leaders to drive the development of these innovative treatmentsInauguration Symposium for Theranostics Trial Center
The upcoming symposium will bring together national and international experts in the field of onco-theranostics, including pre-clinical and translational researchers, nuclear medicine specialists, oncologists, radiologists, medical physicists and representatives of Swedish pharmaceutical companies, patient organizations and decision-makers. Topics include advancements in targeting substances for diagnostic and therapeutic purposes, dosimetry, whole-body PET, and clinical applications.Dubai Radiotheranostics Summit
Radiotheranostics, radiopharmaceuticals with antitumour effects, have seen rapid development over the past decade. The Dubai Radiotheranostics Summit aims to raise awareness, as well as address challenges and opportunities around this cancer care approach. By gathering multiple points of view from specialists from the field, we aim to give a broad perspective of how to accelerate the setting-up of the structure to enhance patient access.PDDS 2025
PDDS 2025 will feature a comprehensive program covering a wide array of topics, from the latest developments in drug delivery systems to advances in biotherapeutics and the impact of COVID-19 on the pharmaceutical industry. The event will delve into areas such as cellular targeting, vaccine design, pharmaceutical microbiology, and nanotechnology, ensuring a holistic approach to understanding the challenges and innovations shaping the future of drug delivery. By addressing both the scientific and regulatory aspects of the industry, the conference aims to provide a complete overview of the current landscape and future possibilities.TRP: Target Selection & Drug Design Summit
Diversifying Radiopharmaceutical Pipelines by Characterizing Novel Radiopharmaceutical Targets While Expanding the Drug Design Toolkit with Cutting-Edge Targeting Strategies, Linker & Chelator Technologies & Illuminating Radiobiological MechanismsTRP 2025
As demand for radiopharmaceuticals increases, the field is working to strengthen isotope supply, enhance patient access and bring more therapeutic candidates to the clinic. Bringing together the industry leaders that are making it all happen, the 4th Targeted Radiopharmaceuticals Summit US returns to San Diego as the largest end-to-end, industry focused platform. Gathering 275+ global stakeholders, sharing exclusive scientific and strategic insights from players including Novartis, AstraZeneca, BMS, Ratio Therapeutics, Alpha-9 Oncology, AdvanCell, Mariana Oncology, Abdera Therapeutics and many more! Discover novel engineering for cutting-edge targeting molecules, increase successful clinical translation and gain clarity on isotope supply in our three dedicated tracks of content Discovery & Preclinical, Translational & Early Stage Clinical and Supply Chain & Late Stage Clinical.26th International Symposium on Radiopharmaceutical Sciences (iSRS)
Taking place in Queensland Australia, this event will include keynote speakers whose interests include: Theranostics, Biomolecular Synthesis, Nuclear Medicine, and more.ESMO Congress 2025
The ESMO Congress is a highly influential global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO 2025 will be a place where groundbreaking discoveries, cutting-edge treatments and a collaborative approach converge to shape the future of cancer care.International Conference on Radiopharmacy and Radiopharmaceuticals
International Conference on Radiopharmacy and Radiopharmaceuticals aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Radiopharmacy and Radiopharmaceuticals. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Radiopharmacy and Radiopharmaceuticals.JP Morgan Health Care Conference
The 43rd Annual Healthcare Conference will take place on January 13-16, 2025 in San Francisco, CA. This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.SNMMI 2025
oin us June 21-24 for the 2025 SNMMI Annual Meeting, where groundbreaking research meets clinical innovation in the heart of New Orleans. This pivotal event unites physicians, technologists, pharmacists, laboratory professionals, scientists, and industry to showcase cutting-edge developments accelerating the path to better patient care. Immerse yourself in: Revolutionary research shaping the future of nuclear medicine and molecular imaging Advanced clinical applications transforming patient care Unparalleled networking opportunities with global thought leaders Don’t miss this opportunity to be at the forefront of nuclear medicine and molecular imaging advancement.Fourth Transatlantic Exchange in Oncology
Leaders from the Dana-Farber Cancer Institute and Gustave Roussy, recognized globally for their expertise, will present on such topics as: Precision Oncology and molecular imaging – early detection; How to go from non-Radio-labeled target to a Radio-labeled active product; Latest clinical applications; and Perspectives from Academia and Industry on Radioligand Therapies. The meeting will be chaired by Professor Toni Choueiri, MD, medical director of International Strategic Initiatives and director of the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School and Professor Karim Fizazi, Gustave Roussy and Université Paris-Saclay, head of the International Academic Network at Gustave Roussy. The Keynote speaker is Michael Morris, MD, FASCO, Prostate Cancer Section Head, Genitourinary Oncology, Steven A. Greenberg Chair in Prostate Cancer Research at Memorial Sloan Kettering Cancer Center (NYC, USA). His keynote presentation will discuss Seeing beyond VISION: Designing Radioligand Therapy trials that yield a survival benefit.TOPIM 2025
The past decades have witnessed remarkable advancements in theranostics, fundamentally transforming patient care by enabling precise targeting and image-guided treatment in the fields of oncology, neurology or autoimmune diseases. Yet, the journey is far from over. Despite tremendous progress, there is significant potential in all areas of theranostics. (i) improving the therapeutic index in radioligand therapy by applying novel radioisotopes, labeling strategies and optimized biologicals, (ii) optimizing MR, ultrasound and multimodality methods, or (iii) applying next-generation cellular constructs. Achieving such breakthroughs demands close collaboration across specialties, bringing us closer to the ultimate goal: fulfilling the promise of image-guided theranostics as the cornerstone of precision medicine.PSMA and Beyond
Held by the University of California - San Francisco, with help from sponsorships from UCLA Health, UCSF Health, and the Prostate Cancer FoundationASCO Annual Meeting
ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwideRLT Components
RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.
There are several Components to a RLT that are simply demonstrated in the truck diagram including:
- Cancer Targets
- Ligand (demonstrated as the Truck GPS set to find a specific Target)
- Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
- Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
- Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
- Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).
To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.
Education
Stats
Sponsors
.svg)
